Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Ivan Babic

h-index 2 View on Semantic Scholar

We have 4 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors

The results support IND-enabling studies of ADT-030 as a monotherapy or in combination with standard-of-care treatments for patients with a broad range of RAS-driven cancers, and especially for patients who relapsed after RAS inhibitor treatment.

Xi Chen, D. S. Bandi, G. Nagaraju et al. · 0 citations
Open access Jul 2026

Targeting the NuRD Component, CHD4, Impairs Foxp3+ Treg Cell Production and Function and Promotes Anti-Tumor Immunity

CHD4 is identified as a critical epigenetic regulator of Treg lineage stability and pharmacological targeting of the CHD4/NuRD axis is established as a promising strategy to selectively disrupt tumor-associated Tregs and enhance antitumor immunity.

Yan Xiong, Li-Qing Wang, Martina Minisini et al. · 0 citations
Jul 2026

Abstract A089: ADT-1004: A mechanistically distinct pan-RAS inhibitor with the potential to escape resistance and mitigate on-target toxicities that limit efficacy and safety of other RAS inhibitors

An orally bioavailable prodrug of ADT-1004, ADT-1004, demonstrated favorable tolerability and suppressed tumor growth in orthotopic and patient-derived xenograft models of pancreatic cancer, accompanied by reductions in activated RAS and p-ERK levels (Mol Cancer, 2025).

Junwei Wang, Xi Chen, Bandi D. S. Reddy et al. · 0 citations
Open access Jul 2026

Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy

These studies establish selective inhibition of the PLK1 Polo-box domain as a viable therapeutic strategy, provide in vivo proof-of-concept for the REPLACE approach, and identify abbapolins as promising leads for advanced prostate cancer.

George Merhej, Gurusankar Ramamoorthy, Danda Chapagai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.